查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1403409

乳癌診斷市場至2030年的預測：按產品、類型、應用、最終用戶和地區進行的全球分析

Breast Cancer Diagnostics Market Forecasts to 2030 - Global Analysis By Product, Type, Application, End User and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 200+ Pages | 商品交期: 2-3個工作天內

價格

根據 Stratistics MRC 的資料，2023年全球乳癌診斷市場規模將達到 47.5 億美元，預計到2030年將達到 89.2 億美元，預測期內年複合成長率為 9.4%。

乳癌診斷對於早期發現和有效的治療計劃非常重要。早期發現可以及時干預，提高存活率並減少積極治療的需要。診斷劑可以幫助表徵腫瘤類型、指導個體化治療並監測治療反應。它使醫療保健專業人員能夠根據患者的個別需求量身定做干涉措施並最佳化結果。

據美國癌症協會表示，2021年，僅美國就有約 281,550 例乳腺癌新診斷和 49,290 例相關死亡。

乳癌發生率上升

乳癌盛行率的上升是乳癌診斷的重要催化劑。隨著全球病例數量的增加，對先進診斷技術和篩檢方法的需求也在增加。早期檢測對於有效治療非常重要，並且推動乳房X光攝影、分子診斷和切片檢查等診斷工具的創新。對準確、及時的乳癌診斷的需求激增是推動市場擴張的關鍵因素。

過度診斷和誤報的風險

過度診斷或假陽性是癌症存在的錯誤指示，但實際上癌症並不存在。這可能會給患者帶來不必要的情緒困擾、焦慮和恐懼。此外，它們經常引發切片檢查等侵入性手術，使患者面臨潛在的身體傷害和不適。生活在對癌症的恐懼中的心理負擔和額外醫學檢查的經濟負擔可能會影響患者的整體健康。

整合人工智慧和機器學習

人工智慧（AI）和機器學習（ML）在乳癌診斷中的整合透過分析複雜的資料模式，支援早期檢測和個體化治療策略，提高了診斷過程的準確性和效率。人工智慧和機器學習使醫療保健專業人員能夠做出更資訊的決策，改善患者的治療結果。這項進步不僅有望徹底改變診斷能力，還將促進市場創新並提高準確性和有效性，以解決全球最普遍和最關鍵的健康挑戰之一。

診斷費用高

乳癌診斷需要先進的技術，例如乳房X光攝影、MRI和基因檢測，這些技術的開發、維護和操作成本高昂。這些診斷工具的複雜性加上嚴格的品質標準導致了昂貴的程序。這種財務障礙限制了及時發現和治療，並對患者的治療結果產生負面影響。因此，市場面臨著實現廣泛普及，改善患者治療結果以及解決乳癌對公共衛生的廣泛影響的挑戰。

COVID-19 的影響

COVID-19 的疫情對市場產生了重大影響。常規篩檢的延遲、患者就診的減少以及醫療資源緊張導致乳癌確診病例減少。供應鏈和醫療保健服務的中斷也影響市場的成長。然而，意識的提高和遠端醫療和人工智慧診斷等技術進步推動乳癌大流行後的復甦並重塑乳癌診斷的格局。

預計切片檢查市場在預測期內將是最大的

切片檢查領域預計將經歷良好的成長。切片檢查是確認惡性的重要步驟。從受影響的區域取出一小塊組織樣本並在顯微鏡下檢查。切片檢查結果指南治療決策，並幫助醫療保健專業人員為診斷為乳癌的患者提供有效的治療和干涉措施。早期和準確的切片檢查結果對於確保及時和適當的乳癌治療非常重要。

預計熱成像產業在預測期內將呈現最高的年複合成長率。

預計熱成像領域在預測期內將以最高的年複合成長率成長。乳癌診斷中的熱成像技術使用紅外線影像來檢測乳房組織的熱模式和潛在異常。熱成像是一種非侵入性、無輻射的技術，可突顯與血流和細胞活動相關的溫度變化。非接觸和無壓力的性質使體驗更加舒適，並且是傳統診斷工具的寶貴輔助。

佔有率最大的地區

由於意識的提高、醫療保健支出的增加以及診斷技術的進步，預計亞太地區將在預測期內佔據最大的市場佔有率。亞太地區是 GE Healthcare、Abbott Laboratories、Siemens Healthineers 和 Roche Diagnostics 等主要企業的所在地。這些公司提供各種診斷技術。由於亞太地區患者人數不斷成長以及政府為提高癌症意識和篩檢所做的努力，預計該市場將繼續呈上升趨勢。

年複合成長率最高的地區：

預計北美在預測期內的年複合成長率最高。在北美，美國佔有最大的市場佔有率。該地區擁有多個市場參與者，包括 Bio-Rad Laboratories、Agendia、Genomic Health 和 Myriad Genetics。這些主要企業採取併購、聯盟等策略來獲得更大的市場佔有率。乳癌是大多數美國國家最常診斷的癌症。乳癌盛行率的上升，加上北美醫療保健基礎設施的開拓，預計將推動整體市場的成長。

提供免費客製化：

訂閱此報告的客戶可以存取以下免費自訂選項之一：

  • 公司簡介
    • 其他市場參與者的綜合分析（最多3家公司）
    • 主要企業SWOT分析（最多3家公司）
  • 區域細分
    • 根據客戶興趣對主要國家的市場估計、預測和年複合成長率（註：基於可行性檢查）
  • 競爭基準化分析
    • 根據產品系列、地理分佈和策略聯盟對主要企業基準化分析

目錄

第1章 執行摘要

第2章 前言

  • 概述
  • 相關利益者
  • 調查範圍
  • 調查方法
    • 資料探勘
    • 資料分析
    • 資料檢驗
    • 研究途徑
  • 調查來源
    • 主要調查來源
    • 二次調查來源
    • 先決條件

第3章 市場趨勢分析

  • 促進因素
  • 抑制因素
  • 機會
  • 威脅
  • 產品分析
  • 應用分析
  • 最終用戶分析
  • 新興市場
  • 新型冠狀病毒感染疾病（COVID-19）的影響

第4章 波特五力分析

  • 供應商的議價能力
  • 買方議價能力
  • 替代品的威脅
  • 新進入者的威脅
  • 競爭公司之間的敵對關係

第5章 全球乳癌診斷市場：依產品

  • 以儀器為基礎的產品
  • 基於平台的產品

第6章 全球乳癌診斷市場：依類型

  • 切片檢查
    • 針吸切片
    • 手術切片檢查
  • 影像
  • 驗血
    • 生物標記測試
    • 循環性腫瘤細胞（CTC）檢測
  • 基因組測試
    • 基因表現
    • 下一代定序（NGS）
  • 核醫學診斷
    • 前哨淋巴結活體組織切片
    • 正子斷層掃描（PET）
  • 組織病理學
  • 其他類型

第7章 全球乳癌診斷市場：依應用分類

  • 篩檢
    • 乳房X光照相術
    • 乳房自我檢測（BSE）
    • 臨床乳房檢查（CBE）
    • 分子乳房影像（MBI）
    • 乳腺超音波檢查
  • 診斷影像
    • X光
    • 磁振造影（MRI）
    • 電腦斷層掃描（CT）掃描
    • 超音波
    • 分子成像技術
  • 熱成像
  • 其他用途

第8章 全球乳癌診斷市場：依最終用戶分類

  • 醫院和診所
  • 診斷中心和醫學實驗室
  • 其他最終用戶

第9章 全球乳癌診斷市場：依地區

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 義大利
    • 法國
    • 西班牙
    • 其他歐洲國家
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 紐西蘭
    • 韓國
    • 其他亞太地區
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 南美洲其他地區
  • 中東和非洲
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 卡達
    • 南非
    • 其他中東和非洲

第10章 主要進展

  • 合約、夥伴關係、協作和合資企業
  • 收購和合併
  • 新產品發布
  • 業務擴展
  • 其他關鍵策略

第11章 公司簡介

  • Hologic Inc
  • GE Healthcare
  • Siemens Healthineers
  • Philips Healthcare
  • Abbott Laboratories
  • Roche Diagnostics
  • Thermo Fisher Scientific
  • PerkinElmer Inc.
  • Agilent Technologies
  • Becton, Dickinson and Company（BD）
  • Myriad Genetics Inc.
  • Sysmex Corporation
  • NanoString Technologies
  • Genomic Health
  • Illumina Inc.
  • Bio-Rad Laboratories
  • Sienna Cancer Diagnostics
  • Cepheid
  • Invivo Corporation
  • Aurora Diagnostics
Product Code: SMRC24634

According to Stratistics MRC, the Global Breast Cancer Diagnostics Market is accounted for $4.75 billion in 2023 and is expected to reach $8.92 billion by 2030 growing at a CAGR of 9.4% during the forecast period. Breast cancer diagnostics are crucial for early detection and effective treatment planning. Early identification enables timely intervention, improving survival rates and reducing the need for aggressive treatments. Diagnostics aid in characterizing tumor types, guiding personalized therapies, and monitoring treatment response. They empower healthcare professionals to tailor interventions to individual patient needs, optimizing outcomes.

According to the American Cancer Society, it is estimated that approximately 281,550 new cases of breast cancer will be diagnosed in 2021, with an expected 49,290 related deaths in the U.S. alone.

Market Dynamics:

Driver:

Rising incidence of breast cancer

The escalating prevalence of breast cancer is a key catalyst for the breast cancer diagnostics. With a rising number of cases globally, there is an increasing demand for advanced diagnostic technologies and screening methods. Early detection is crucial for effective treatment, driving innovation in diagnostic tools such as mammography, molecular diagnostics, and biopsy. This surge in demand for accurate and timely breast cancer diagnosis is a significant factor fueling the expansion of the market.

Restraint:

Risk of overdiagnosis & false positives

Overdiagnosis and false positive result erroneously indicates the presence of cancer when it is not actually present. This can lead to unnecessary emotional distress, anxiety, and fear for the patient. Moreover, it often triggers further invasive procedures such as biopsies, exposing individuals to potential physical harm and discomfort. The psychological toll of living with the fear of cancer and the financial burden of additional medical tests can impact a patient's overall well-being.

Opportunity:

Integration of artificial intelligence & machine learning

The integration of artificial intelligence (AI) and machine learning (ML) in breast cancer diagnostics enhance the accuracy and efficiency of diagnostic processes by analyzing complex data patterns, aiding in early detection, and personalized treatment strategies. AI and ML empower healthcare professionals to make more informed decisions, leading to improved patient outcomes. This advancement not only revolutionizes diagnostic capabilities but also fosters innovation in the market, promising enhanced precision and effectiveness in addressing one of the most prevalent and critical health challenges worldwide.

Threat:

High cost of diagnostic procedures

Breast Cancer Diagnostics procedures involve advanced technologies such as mammography, MRI, and genetic testing, which incur high development, maintenance, and operational expenses. The intricate nature of these diagnostic tools, coupled with stringent quality standards, results in expensive procedures. This financial barrier limits timely detection and treatment, negatively impacting patient outcomes. As a result, the market faces challenges in achieving widespread adoption, improving patient outcomes, and addressing the broader public health impact of breast cancer.

COVID-19 Impact

The COVID-19 pandemic has significantly impacted the market. Delays in routine screenings, reduced patient visits, and strained healthcare resources have led to a decline in the diagnosis of breast cancer cases. Disruptions in supply chains and healthcare services have also affected the market's growth. However, increased awareness and technological advancements, such as telemedicine and AI-driven diagnostics, have driven recovery and reshaped the landscape for breast cancer diagnostics in the post-pandemic era.

The biopsy segment is expected to be the largest during the forecast period

The biopsy segment is estimated to have a lucrative growth. Biopsy is a crucial procedure for confirming malignancy. It involves extracting a small tissue sample from the affected area for examination under a microscope. Biopsy results guide treatment decisions, helping healthcare professionals tailor effective therapies and interventions for patients diagnosed with breast cancer. Early and accurate biopsy results are pivotal in ensuring timely and appropriate management of breast cancer.

The thermography segment is expected to have the highest CAGR during the forecast period

The thermography segment is anticipated to witness the highest CAGR growth during the forecast period. Thermography in breast cancer diagnostics involves using infrared imaging to detect heat patterns and potential abnormalities in breast tissue. It is a non-invasive and radiation-free technique that highlights variations in temperature associated with blood flow and cellular activity. Its non-contact nature and lack of compression contribute to a more comfortable experience, making it a valuable adjunct to traditional diagnostic tools.

Region with largest share:

Asia Pacific is projected to hold the largest market share during the forecast period owing to the rising awareness, increased healthcare expenditure, and advancements in diagnostic technologies. It has the presence of top most players namely GE Healthcare, Abbott Laboratories, Siemens Healthineers and Roche Diagnostics. These companies often offer a diverse range of diagnostic technologies. The market is expected to continue its upward trajectory, driven by a growing patient population and government initiatives promoting cancer awareness and screening in the Asia-Pacific region.

Region with highest CAGR:

North America is projected to have the highest CAGR over the forecast period. The U.S. held the largest market share of the market in North America. The region is home to several market players including Bio-Rad Laboratories, Agendia, Genomic Health and Myriad Genetics. These key companies are adopting strategies such as mergers and acquisitions and partnerships, to acquire a larger market share. Breast cancer is the most commonly diagnosed cancer in most American countries. The rising prevalence of breast cancer, coupled with the development of healthcare infrastructure in North America, is expected to drive overall market growth.

Key players in the market:

Some of the key players profiled in the Breast Cancer Diagnostics Market include Hologic Inc, GE Healthcare, Siemens Healthineers, Philips Healthcare, Abbott Laboratories, Roche Diagnostics, Thermo Fisher Scientific, PerkinElmer Inc., Agilent Technologies, Becton, Dickinson and Company (BD), Myriad Genetics Inc., Sysmex Corporation, NanoString Technologies, Genomic Health, Illumina Inc., Bio-Rad Laboratories, Sienna Cancer Diagnostics, Cepheid, Invivo Corporation and Aurora Diagnostics.

Key Developments:

In December 2023, GE HealthCare released a new, all-in-one platform of artificial intelligence (AI) apps to support clinicians with breast cancer detection and improved workflow productivity called MyBreastAI Suite.

In May 2023, Pfizer and Thermo Fisher Scientific Inc. have entered into a collaboration agreement to help increase local access to next-generation sequencing (NGS)-based testing for lung and breast cancer patients in more than 30 countries across Latin America, Africa, the Middle East and Asia where advanced genomic testing has previously been limited or unavailable.

Products Covered:

  • Instrument-based Products
  • Platform-based Products

Types Covered:

  • Biopsy
  • Imaging
  • Blood Tests
  • Genomic Tests
  • Nuclear Medicine Diagnostics
  • Histopathology
  • Other Types

Applications Covered:

  • Screening
  • Diagnostic Imaging
  • Thermography
  • Other Applications

End Users Covered:

  • Hospitals & Clinics
  • Diagnostic Centers & Medical Laboratories
  • Other End Users

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 Product Analysis
  • 3.7 Application Analysis
  • 3.8 End User Analysis
  • 3.9 Emerging Markets
  • 3.10 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Breast Cancer Diagnostics Market, By Product

  • 5.1 Introduction
  • 5.2 Instrument-based Products
  • 5.3 Platform-based Products

6 Global Breast Cancer Diagnostics Market, By Type

  • 6.1 Introduction
  • 6.2 Biopsy
    • 6.2.1 Needle Biopsy
    • 6.2.2 Surgical Biopsy
  • 6.3 Imaging
  • 6.4 Blood Tests
    • 6.4.1 Biomarker Testing
    • 6.4.2 Circulating Tumor Cells (CTCs) Testing
  • 6.5 Genomic Tests
    • 6.5.1 Gene Expression Profiling
    • 6.5.2 Next-Generation Sequencing (NGS)
  • 6.6 Nuclear Medicine Diagnostics
    • 6.6.1 Sentinel Lymph Node Biopsy
    • 6.6.2 Positron Emission Tomography (PET)
  • 6.7 Histopathology
  • 6.8 Other Types

7 Global Breast Cancer Diagnostics Market, By Application

  • 7.1 Introduction
  • 7.2 Screening
    • 7.2.1 Mammography
    • 7.2.2 Breast Self-Examination (BSE)
    • 7.2.3 Clinical Breast Examination (CBE)
    • 7.2.4 Molecular Breast Imaging (MBI)
    • 7.2.5 Breast Ultrasound
  • 7.3 Diagnostic Imaging
    • 7.3.1 X-ray
    • 7.3.2 Magnetic Resonance Imaging (MRI)
    • 7.3.3 Computed Tomography (CT) Scan
    • 7.3.4 Ultrasound
    • 7.3.5 Molecular Imaging Techniques
  • 7.4 Thermography
  • 7.5 Other Applications

8 Global Breast Cancer Diagnostics Market, By End User

  • 8.1 Introduction
  • 8.2 Hospitals & Clinics
  • 8.3 Diagnostic Centers & Medical Laboratories
  • 8.4 Other End Users

9 Global Breast Cancer Diagnostics Market, By Geography

  • 9.1 Introduction
  • 9.2 North America
    • 9.2.1 US
    • 9.2.2 Canada
    • 9.2.3 Mexico
  • 9.3 Europe
    • 9.3.1 Germany
    • 9.3.2 UK
    • 9.3.3 Italy
    • 9.3.4 France
    • 9.3.5 Spain
    • 9.3.6 Rest of Europe
  • 9.4 Asia Pacific
    • 9.4.1 Japan
    • 9.4.2 China
    • 9.4.3 India
    • 9.4.4 Australia
    • 9.4.5 New Zealand
    • 9.4.6 South Korea
    • 9.4.7 Rest of Asia Pacific
  • 9.5 South America
    • 9.5.1 Argentina
    • 9.5.2 Brazil
    • 9.5.3 Chile
    • 9.5.4 Rest of South America
  • 9.6 Middle East & Africa
    • 9.6.1 Saudi Arabia
    • 9.6.2 UAE
    • 9.6.3 Qatar
    • 9.6.4 South Africa
    • 9.6.5 Rest of Middle East & Africa

10 Key Developments

  • 10.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 10.2 Acquisitions & Mergers
  • 10.3 New Product Launch
  • 10.4 Expansions
  • 10.5 Other Key Strategies

11 Company Profiling

  • 11.1 Hologic Inc
  • 11.2 GE Healthcare
  • 11.3 Siemens Healthineers
  • 11.4 Philips Healthcare
  • 11.5 Abbott Laboratories
  • 11.6 Roche Diagnostics
  • 11.7 Thermo Fisher Scientific
  • 11.8 PerkinElmer Inc.
  • 11.9 Agilent Technologies
  • 11.10 Becton, Dickinson and Company (BD)
  • 11.11 Myriad Genetics Inc.
  • 11.12 Sysmex Corporation
  • 11.13 NanoString Technologies
  • 11.14 Genomic Health
  • 11.15 Illumina Inc.
  • 11.16 Bio-Rad Laboratories
  • 11.17 Sienna Cancer Diagnostics
  • 11.18 Cepheid
  • 11.19 Invivo Corporation
  • 11.20 Aurora Diagnostics

List of Tables

  • Table 1 Global Breast Cancer Diagnostics Market Outlook, By Region (2021-2030) ($MN)
  • Table 2 Global Breast Cancer Diagnostics Market Outlook, By Product (2021-2030) ($MN)
  • Table 3 Global Breast Cancer Diagnostics Market Outlook, By Instrument-based Products (2021-2030) ($MN)
  • Table 4 Global Breast Cancer Diagnostics Market Outlook, By Platform-based Products (2021-2030) ($MN)
  • Table 5 Global Breast Cancer Diagnostics Market Outlook, By Type (2021-2030) ($MN)
  • Table 6 Global Breast Cancer Diagnostics Market Outlook, By Biopsy (2021-2030) ($MN)
  • Table 7 Global Breast Cancer Diagnostics Market Outlook, By Needle Biopsy (2021-2030) ($MN)
  • Table 8 Global Breast Cancer Diagnostics Market Outlook, By Surgical Biopsy (2021-2030) ($MN)
  • Table 9 Global Breast Cancer Diagnostics Market Outlook, By Imaging (2021-2030) ($MN)
  • Table 10 Global Breast Cancer Diagnostics Market Outlook, By Blood Tests (2021-2030) ($MN)
  • Table 11 Global Breast Cancer Diagnostics Market Outlook, By Biomarker Testing (2021-2030) ($MN)
  • Table 12 Global Breast Cancer Diagnostics Market Outlook, By Circulating Tumor Cells (CTCs) Testing (2021-2030) ($MN)
  • Table 13 Global Breast Cancer Diagnostics Market Outlook, By Genomic Tests (2021-2030) ($MN)
  • Table 14 Global Breast Cancer Diagnostics Market Outlook, By Gene Expression Profiling (2021-2030) ($MN)
  • Table 15 Global Breast Cancer Diagnostics Market Outlook, By Next-Generation Sequencing (NGS) (2021-2030) ($MN)
  • Table 16 Global Breast Cancer Diagnostics Market Outlook, By Nuclear Medicine Diagnostics (2021-2030) ($MN)
  • Table 17 Global Breast Cancer Diagnostics Market Outlook, By Sentinel Lymph Node Biopsy (2021-2030) ($MN)
  • Table 18 Global Breast Cancer Diagnostics Market Outlook, By Positron Emission Tomography (PET) (2021-2030) ($MN)
  • Table 19 Global Breast Cancer Diagnostics Market Outlook, By Histopathology (2021-2030) ($MN)
  • Table 20 Global Breast Cancer Diagnostics Market Outlook, By Other Types (2021-2030) ($MN)
  • Table 21 Global Breast Cancer Diagnostics Market Outlook, By Application (2021-2030) ($MN)
  • Table 22 Global Breast Cancer Diagnostics Market Outlook, By Screening (2021-2030) ($MN)
  • Table 23 Global Breast Cancer Diagnostics Market Outlook, By Mammography (2021-2030) ($MN)
  • Table 24 Global Breast Cancer Diagnostics Market Outlook, By Breast Self-Examination (BSE) (2021-2030) ($MN)
  • Table 25 Global Breast Cancer Diagnostics Market Outlook, By Clinical Breast Examination (CBE) (2021-2030) ($MN)
  • Table 26 Global Breast Cancer Diagnostics Market Outlook, By Molecular Breast Imaging (MBI) (2021-2030) ($MN)
  • Table 27 Global Breast Cancer Diagnostics Market Outlook, By Breast Ultrasound (2021-2030) ($MN)
  • Table 28 Global Breast Cancer Diagnostics Market Outlook, By Diagnostic Imaging (2021-2030) ($MN)
  • Table 29 Global Breast Cancer Diagnostics Market Outlook, By X-ray (2021-2030) ($MN)
  • Table 30 Global Breast Cancer Diagnostics Market Outlook, By Magnetic Resonance Imaging (MRI) (2021-2030) ($MN)
  • Table 31 Global Breast Cancer Diagnostics Market Outlook, By Computed Tomography (CT) Scan (2021-2030) ($MN)
  • Table 32 Global Breast Cancer Diagnostics Market Outlook, By Ultrasound (2021-2030) ($MN)
  • Table 33 Global Breast Cancer Diagnostics Market Outlook, By Molecular Imaging Techniques (2021-2030) ($MN)
  • Table 34 Global Breast Cancer Diagnostics Market Outlook, By Thermography (2021-2030) ($MN)
  • Table 35 Global Breast Cancer Diagnostics Market Outlook, By Other Applications (2021-2030) ($MN)
  • Table 36 Global Breast Cancer Diagnostics Market Outlook, By End User (2021-2030) ($MN)
  • Table 37 Global Breast Cancer Diagnostics Market Outlook, By Hospitals & Clinics (2021-2030) ($MN)
  • Table 38 Global Breast Cancer Diagnostics Market Outlook, By Diagnostic Centers & Medical Laboratories (2021-2030) ($MN)
  • Table 39 Global Breast Cancer Diagnostics Market Outlook, By Other End Users (2021-2030) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.